Indegene Limited has announced that its shareholders have approved a special resolution for the variation in utilization of Initial Public Offering (IPO) proceeds. The decision was made through a remote e-voting postal ballot that concluded on August 12, 2025.

Voting Results

The voting results revealed strong support for the resolution:

The total votes polled represented 38.53% of the company's outstanding shares, with 92,487,493 votes cast. An overwhelming 99.99% of the votes were in favor of the resolution, while only 0.01% were against it.

Shareholder Participation

Out of 154,043 equity shareholders eligible to vote as of the July 4, 2025 cut-off date:

• 718 members voted in favor of the resolution
• 82 members voted against it

E-Voting Process

The e-voting period ran from July 14 to August 12, 2025, allowing shareholders to cast their votes electronically. The process was conducted in compliance with the Companies Act, 2013, and SEBI regulations.

Scrutinizer's Report

Madhwesh K, a Practicing Company Secretary from Bengaluru, acted as the Scrutinizer for the postal ballot process. The Scrutinizer's report, dated August 13, 2025, confirmed the validity of the voting process and results.

Transparency and Disclosure

In line with regulatory requirements, Indegene Limited has made the voting results and Scrutinizer's report available on the company's website ( www.indegene.com ) and the National Securities Depository Limited's website ( www.evoting.nsdl.com ).

The approval of this resolution allows Indegene Limited to modify the utilization of its IPO proceeds, potentially enabling the company to adapt its financial strategies to current market conditions or business needs. Shareholders' strong support for this decision indicates confidence in the management's plans for fund allocation.

Indegene Limited, headquartered in Bengaluru, continues to maintain transparency with its investors through timely disclosures and adherence to regulatory requirements.

Indegene Limited , a leading digital-first, life sciences commercialization company, reported its financial results for the first quarter, showcasing steady growth and strategic initiatives.

Financial Highlights

• Revenue reached INR 7,068.00 million, representing a 1.8% growth in USD terms and 0.7% in INR terms quarter-on-quarter.
• EBITDA stood at INR 1,536.00 million, with a 0.7% quarter-on-quarter growth.
• Profit After Tax (PAT) came in at INR 1,164.00 million.
• Cash and cash equivalents investments crossed $200 million, reaching INR 17,280.00 million.

Strategic Developments

Indegene introduced 'Tectonic', a new commercial content creation initiative that generated over USD 1.00 million in revenue from two top-20 customers during the quarter. This initiative aims to move up the marketing value chain and capture more upstream work traditionally done by specialized healthcare agencies.

Segment Performance

• Enterprise segments (Enterprise Commercial Solutions and Enterprise Medical Solutions) contributed 86.6% of revenue and grew 3.5% quarter-on-quarter.
• Brand Activation segment (formerly Omnichannel Activation) experienced a 21.6% degrowth due to project deferrals from regulatory hurdles and project conclusions.

Client Metrics

• The largest customer grew by 4.3% quarter-on-quarter.
• Top 5 accounts showed a 0.6% growth, reversing the previous quarter's trend.
• The company secured two large deal wins exceeding USD 3.00 million Annual Contract Value (ACV) and four deals in the USD 1.00-3.00 million range.

Industry Outlook and AI Integration

Manish Gupta, Chairman and CEO of Indegene, commented on the industry outlook: "We see no change in the industry outlook. Directionally, the pressure remains on drug pricing and hence, pharma operations to be more efficient."

The company is actively incorporating AI into its solutions across medical affairs, regulatory, safety, and commercial operations through its Cortex platform. This integration is expected to play a significant role in differentiating Indegene and enabling it to capture a larger market share in the medium term.

Future Focus

Indegene's management emphasized their commitment to growth and reinvestment in capabilities such as Tectonic and AI integration. The company aims to maintain EBITDA margins around 20% in the near term while focusing on revenue growth and market expansion.

As the life sciences industry continues to evolve, Indegene remains well-positioned to capitalize on the increasing demand for digital-first, AI-enabled solutions in commercialization and operations.